

Title:

A Case for Estradiol: Younger Brains in Women with Earlier Menarche and Later Menopause

Authors and Affiliations:

Eileen Luders^{1,2,3,4*} | Inger Sundström Poromaa¹ | Claudia Barth⁵ | Christian Gaser^{6,7,8}

¹Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

²Swedish Collegium for Advanced Study (SCAS), Uppsala, Sweden

³School of Psychology, University of Auckland, Auckland, New Zealand

⁴Laboratory of Neuro Imaging, School of Medicine, University of Southern California, Los Angeles, USA

⁵Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway

⁶Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany

⁷Department of Neurology, Jena University Hospital, Jena, Germany

⁸German Center for Mental Health (DZPG)

**Correspondence should be addressed to:*

Eileen Luders, Ph.D.

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

Email: eileen.lueders@uu.se

Number of Words in Abstract: **158**
Number of Figures: **3**
Number of Tables: **3**
Number of Pages: **21**
Supplemental Material: **4 Tables**

Date of Submission: **October 12th, 2023**

Date of Revision: **March 20th, 2024**

Abstract

The transition to menopause is marked by a gradual decrease of estradiol. At the same time, the risk of dementia increases around menopause and it stands to reason that estradiol (or the lack thereof) plays a significant role for the development of dementia and other age-related neuropathologies. Here we investigated if there is a link between brain aging and estradiol-associated events, such as menarche and menopause. For this purpose, we applied a well-validated machine learning approach in a sample of 1,006 postmenopausal women who were scanned twice approximately two years apart. We observed less brain aging in women with an earlier menarche, a later menopause, and a longer reproductive span (i.e., the time interval between menarche and menopause). These effects were evident both cross-sectionally and longitudinally, which supports the notion that estradiol might contribute to brain preservation. However, more research is required as effects were small and no direct measures of estradiol were obtained in the current study.

Keywords:

brain age; estradiol; machine learning; menarche; MRI; menopause; structural neuroimaging

Introduction

Estradiol is the most potent and prevalent form of estrogen during the reproductive life of a woman¹. Generally speaking, estradiol levels start increasing just before the first menstrual period (menarche) and then plateau on a high level until they start decreasing during perimenopause. After the final menstrual period (i.e., menopause) estradiol levels decrease further and eventually reach plateauing low levels during postmenopause². The risk for dementia in women is known to increase around menopause³⁻⁶ and thus it stands to reason that estradiol plays a significant role for the development of dementia and other age-related neuropathologies. However, scientific studies focused on specific phases (e.g., menarche, pregnancy, menopause) or interventions (oral contraceptives, estrogen modulation therapy, estrogen replacement therapy) paint a rather complex picture, with no consistent evidence that more (estradiol) is always beneficial^{4,7-22}. For example, with particular respect to menarche and menopause, both early onset and late onset have been shown to increase the risk for dementia or to be positively associated with brain aging and cognitive functioning^{4,7-14,18-20}.

To further advance this field of research, the current study set out to determine if there is a link between a woman's estimated brain age (a biological marker of brain health²³) and the reproductive span (i.e., the interval between menarche and menopause when estradiol levels are high). If a lack of estradiol is among the driving factors for diminished brain health later in life, brain age and reproductive span should be inversely related (negative correlation). To be able to relate our findings to others in the literature⁷⁻⁹ and to provide a frame of reference for future studies, we additionally investigated if there is a significant link between estimated brain age and the age at menarche as well as the age at menopause. Assuming a neuroprotective effect of estradiol, we expected that a lower brain age would be linked to an earlier menarche (positive correlation) and to a later menopause (negative correlation). Importantly, our study comprises both cross-sectional and longitudinal components, with follow-up data acquired approximately two years after the initial brain scan. This constitutes a critical extension to existing studies from the UK biobank with a related focus as those studies are solely cross-sectional in nature^{8,9,11,17,18,19}.

Our study was conducted in a sample of 1,006 postmenopausal women whose brain ages were estimated using structural brain images and a well-validated high-dimensional pattern recognition approach, as detailed elsewhere^{24,25}. Briefly, the difference between the estimated brain age and the chronological age yields a so-called brain age gap estimate (BrainAGE) in years. The BrainAGE index is negative if a brain is estimated younger than its chronological age; it is positive if a brain is estimated older than its chronological age. For example, a 50-year-old woman with a BrainAGE index of -3 years shows the aging pattern of a 47-year-old. The BrainAGE algorithm has been shown to be robust and reliable across datasets, age-ranges, and scanner types^{24,26}; it has been successfully applied in a wide range of studies^{24,25,27-29} including those capturing hormonal changes in women^{30,31}. Moreover, the BrainAGE index has been demonstrated to work as a predictor of dementia as well as age-related cognitive decline^{27,32}.

Results

Main Analysis

As shown in **Figure 1** (left), our cross-sectional analyses revealed a significant negative association between BrainAGE and the reproductive span. In other words, brains of women with longer reproductive spans were estimated younger than brains of women with shorter reproductive spans. As also shown in **Figure 1** (right), there was a significant positive association between BrainAGE and age at menarche (i.e., the earlier the menarche, the younger the brain) and a significant negative association between BrainAGE and age at menopause (i.e., the later the menopause, the younger the brain). Statistics are provided in **Table 1**, including the slopes of the regression which indicate different rates of change for menarche and menopause (0.32 and -0.10, respectively): More specifically, for each year younger at menarche, brains are estimated 0.32 years younger (which corresponds to 3.2 years younger for each 10 years). In contrast, for each year older at menopause, brains are estimated 0.1 year younger (which corresponds to 1 year younger for each 10 years).

Table 1. Associations with BrainAGE at the initial brain scan

	R ²	Correlation (r)	Significance (p)	Slope
Reproductive Span	0.01	-0.11	<0.001	-0.11
Age at Menarche	0.02	0.14	<0.001	0.32
Age at Menopause	0.01	-0.09	<0.005	-0.10




Figure 1: Correlations with BrainAGE at the initial brain scan. The x-axes show the reproductive span (age, respectively) in years. Of note, age in the UK Biobank has been rounded to the year, so we added a small random jitter to the x-axes to give a better overview about the age distribution. The y-axes show the BrainAGE index in years, with negative values indicating that brains are estimated younger than their chronological age and positive values indicating that brains are estimated older than their chronological age. Panel A displays a negative link between the BrainAGE index and the reproductive span (the longer the reproductive span, the younger the estimated brain age). Panel B displays a positive link between the BrainAGE index and the age at menarche (the earlier the onset of menarche, the younger the estimated brain age). Panel C displays a negative link between the BrainAGE index and the age at menopause (the later the onset of menopause, the younger the estimated brain age). Hot colors in the density plot indicate a larger overlay of measures; cool colors indicate a smaller overlay. The shaded band is the 95% confidence interval.

As shown in **Figure 2** and **Table 2**, our longitudinal findings confirm the observed cross-sectional relationships. More specifically, Δ BrainAGE was negatively linked to reproductive span and menopause, and positively linked to age at menarche. All associations were significant. Moreover, the slopes of the regression are still somewhat different for menarche and menopause (0.08 and -0.06, respectively), albeit more similar than in the cross-sectional analysis: For each year younger at menarche, brains are estimated 0.08 years younger (0.8 years over 10 years), whereas for each year older at menopause, brains are estimated 0.06 years younger (0.6 years over 10 years).

Table 2. Associations with changes in BrainAGE over 2.35 years

	R ²	Correlation (r)	Significance (p)	Slope
Reproductive Span	0.01	-0.12	<0.001	-0.07
Age at Menarche	<0.01	0.06	0.04	0.08
Age at Menopause	0.01	-0.11	<0.001	-0.06




Figure 2: Correlations with BrainAGE over 2.35 years (Δ BrainAGE). Panel A displays a negative link between the BrainAGE index and reproductive span (the longer the reproductive span, the

smaller the estimated brain age). Panel B displays a positive link between the BrainAGE index and the age at menarche (the earlier the onset of menarche, the younger the estimated brain age). Panel C displays a negative link between the BrainAGE index and the age at menopause (the later the onset of menopause, the younger the estimated brain age). Hot colors in the density plot indicate a larger overlay of measures; cool colors indicate a smaller overlay. The shaded band is the 95% confidence interval.

Sensitivity Analysis

The results described above remained stable when removing the variance associated with the number of live births, hormone replacement therapy, hysterectomy, bilateral oophorectomy, body mass index, diastolic and systolic blood pressure, diabetes, education, income, and a composite lifestyle factor. In other words, when examining the association between BrainAGE and reproductive span, we observed a negative association. Likewise, there was a positive association between BrainAGE and age at menarche and a negative association between BrainAGE and age at menopause. The effects were significant both for the cross-sectional analyses (see **Supplemental Table 1**) and the longitudinal analyses (see **Supplemental Table 2**).

Discussion

Here we assessed links between estimated brain age and milestones in a woman's reproductive life in a well-powered sample of more than a thousand postmenopausal women. We detected less brain aging in women with longer reproductive spans, earlier menarche, and later menopause.

Correspondence with Previous Findings

Our findings are in line with the outcomes of other studies suggesting a longer reproductive span^{8,10,13}, an earlier menarche^{13,14}, as well as a later menopause^{4,8,10-12} to be associated with a

lower risk of developing dementia or better retained cognitive function. Furthermore, given that the BrainAGE index is based on the weighted distribution of gray and whiter matter tissue in the brain, our findings are also in agreement with reports of lower brain volumes as well as higher rates of brain tissue loss during menopause compared to premenopause or in postmenopausal women compared to premenopausal women³³⁻³⁵. In addition, our findings agree with observed effects across the menstrual cycle linking high estradiol levels at ovulation to lower BrainAGE estimates³⁰. Altogether, the outcomes of our study seem to suggest that estradiol contributes to brain health, which is in agreement with other studies reporting positive effects of estradiol on brain health and cognition within the framework of aging and/or menopausal hormone therapy³⁶⁻⁴⁰.

Menarche versus Menopause

In the present study, both an earlier menarche and a later menopause were significantly associated with less brain aging. However, aside from the mere direction of the relationship, menarche and menopause also differ with respect to the strength of their relationship with age (which is reflected in the correlation coefficient) and their rate of change with age (which is reflected in the slope of the regression line). This might indicate somewhat different underlying biological mechanisms and/or confounds. For example, during menopause, in addition to decreasing levels of estradiol, increasing levels of follicle-stimulating hormones may cause an accelerated deposition of amyloid- β and Tau⁴¹, which enhances brain atrophy. Moreover, menopause is marked by disadvantageous alterations in cytokine and T cell profiles⁴², which are linked to an enhanced inflammation.

Possible Implications

Given that estradiol levels start decreasing during perimenopause and further decrease after menopause, our findings may explain why the risk for dementia in women is known to increase around menopause³⁻⁶ and why there is an increased age-independent prevalence of Alzheimer's disease in women compared to men⁴⁰. Moreover, our findings seem to support to the concept of the “window of opportunity”, spanning the years leading up to menopause to the years immediately after menopause, where health interventions (e.g., menopausal hormone treatment) may combat the increased risk for Alzheimer's disease in some women^{5,43-45}. However, at this point, all of this is conjecture. In fact, several large-scale projects have investigated the effects of menopausal hormone treatment on cognitive function and Alzheimer's risk, but results are inconclusive (potentially relevant modulators of treatment outcomes are discussed here^{36,46-51}).

A Word of Caution

Our findings seem promising in the framework of prevention and intervention. However, the effect sizes for the observed associations between estimated brain age and reproductive span, age at menarche, and age at menopause were small. This raises the question of whether the apparent impact of estradiol is clinically meaningful. Perhaps, equally relevant, we wish to emphasize that the study did not measure estradiol directly. Therefore, further research is required, the more so as links between estradiol and brain aging are rather complex as indicated by the outcomes of other studies. For example, it was reported that, compared to no exposure or no dose, exposure to low concentrations of estradiol or low doses of estrogen

enhanced neuronal survival and increased anti-inflammatory markers (i.e., positive links), while exposure to high concentrations of estradiol as well as high doses of estrogen had the opposite effect (i.e., negative links)^{21,22}. Another study reported U-shaped curves suggesting that both early and late menarche are associated with an increased risk for dementia (i.e., positive and negative links)⁸. And yet another study reported either negative links or missing links between age at menarche and brain aging depending on the potential confounds accounted for⁷. Interestingly, this latter study also reported that, in carriers of the apolipoprotein E type 4 allele (APOE e4), higher levels of estradiol at menopause were associated with increased brain aging (positive link). In contrast, in non-carriers, higher levels of estradiol at menopause were associated with decreased brain aging (negative link)⁷.

Conclusion

Our study revealed less brain aging in women with a larger reproductive span, earlier menarche, and later menopause. Thus, sex hormones – potentially estradiol – may contribute to brain health. However, follow-up research is required because effects in the current study were small, estradiol was not directly examined, and female brain health may be modulated by other factors than estradiol^{2,52,53}. Moreover, to paint a more complete picture and expand an understudied field research, future research focussing on specific time frames surrounding menopause, such as perimenopause (i.e., the time preceding the final menstrual period) or early postmenopause (e.g., the initial year after menopause) versus late menopause (e.g., ten years after menopause) would be desirable. Last but not least, the UK Biobank is biased

towards healthy⁵⁴ and more socioeconomically privileged individuals⁵⁴ with a predominant white ethnic background⁵⁴, which affects the generalizability of the findings.

Methods

Sample

The study is based on a carefully selected sample of postmenopausal women from the UK Biobank (<https://www.ukbiobank.ac.uk/>) which was accessed under application number #41655. The UK Biobank is a biomedical database and research resource that contains genetic, lifestyle and health information from half a million people. In the UK Biobank cohort, 94.6% of participants are of white ethnicity⁵⁴. For general ethnic information, see <https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=21000>; for ethnic information on all women with available longitudinal data, see **Supplemental Table 3**. The UK Biobank holds the ethical approval from the North West Multi-Centre Research Ethics Committee (MREC) and is in possession of the informed consents. Written informed consent was obtained from all participants.

Exclusion criteria for the current study were pre-existing neurological or psychiatric diagnoses as per UK Biobank data fields #41202-0.0 to #41202-0.78. Inclusion criteria for the current study were women with available longitudinal data as well as information on age at menarche and age at menopause. In addition, to further increase the homogeneity of the sample, we excluded women whose age at menarche was younger than 10 or older than 18, or whose age at menopause was younger than 45 or older than 60. This resulted in a final sample size of 1,006 women. **Figure 3** summarizes the steps related to the sample selection; **Table 3** provides information on the final sample.




Figure 3. Flowchart of sample selection.

Table 3. Sample characteristics

Variable	Descriptive Statistics
age at the initial brain scan*	63.20 ± 6.42 years
age at the follow-up brain scan*	65.54 ± 6.37 years
age at menarche*	13.02 ± 1.53 years
age at menopause*	51.41 ± 3.23 years
reproductive span*	38.39 ± 3.55 years
number of live births*	1.75 ± 1.16

number of women with hormone replacement therapy	yes: 306 no: 700
number of women with hysterectomy	yes: 48 no: 958
number of women with bilateral oophorectomy	yes: 37 no: 969

*statistics provided as mean \pm standard deviation

Image Acquisition and Processing

For each woman, one initial brain scan and one follow-up brain scan – approximately two years apart (mean \pm SD: 2.35 \pm 6.12 years) – were obtained *after* menopause. Brain images were acquired on a 3 Tesla Siemens Skyra scanner using a 32-channel head coil, as described elsewhere⁵⁵ (see also: http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/bmri_V4_23092014.pdf). Using the T1-weighted images, we applied a number of processing routines implemented in the CAT12 toolbox⁵⁶ (version 12.8) that resulted in bias-corrected, spatially normalized, and tissue-classified brain images, as detailed elsewhere^{24,31}. The affinely normalized gray and white matter partitions were then smoothed using a 4 and 8 mm full-width-at-half-maximum (FWHM) Gaussian kernel, and image resolution was set to 4 and 8 mm. For further data reduction, we applied a principal component analysis (PCA) using singular value decomposition to all the models using $n-1$ PCA components (n = minimum of voxel number or sample size). For the estimation of the BrainAGE index, we employed a Gaussian Process Regression (GPR) that uses a linear covariance function, a constant mean function, and a Gaussian likelihood function; hyperparameters were set to 100 for the constant mean function and to -1 for the likelihood function⁵⁷. As training data, we selected 3,046 individuals from the UK Biobank where two time points were available and applied a 10-fold validation approach separately for the initial and follow-up brain scan. To estimate the individual brain ages, eight models based on the aforementioned sets of images (i.e., gray matter/white matter, 4 mm/8 mm Gaussian kernel, and 4 mm/8 mm image resolution) were combined using a general linear model where the weights of the models were derived by maximizing the variance to the parameter of interest (e.g., menopause). The difference between the resulting estimated brain age and the chronological age was then calculated as the BrainAGE index (in years).

Statistical Analyses

After computing the BrainAGE index for all 1,006 women at initial and follow-up scan, we first removed the linear age trend that is typically seen in BrainAGE estimation. Then, we conducted two analysis streams using linear regressions, one cross-sectional and one longitudinal. For the cross-sectional stream, we tested if there is a significant link between the BrainAGE index at the initial brain scan and the reproductive span. In addition, we tested if there is a significant link between the BrainAGE index at the initial brain scan and the age at menarche as well as the age at menopause. For the longitudinal stream, we first subtracted the BrainAGE index at the initial brain scan from the BrainAGE index at the follow-up brain scan, which resulted in a Δ BrainAGE index for each individual. This method, often referred to as “change score” analysis, produces statistical results that are comparable to those resulting from a repeated-measures ANOVA with two time points. Using the Δ BrainAGE index, we then tested for significant links with the reproductive span, the age at menarche, and the age at menopause. For all analyses, alpha was set at 0.05 (two-tailed).

Sensitivity Analyses

To determine if our results remain stable and significant when accounting for potential confounds known to affect brain health, we repeated the aforementioned cross-sectional and longitudinal analyses for reproductive span, menarche, and menopause using additional parameters. More specifically, we removed the variance associated with the number of live births⁵⁸ (UK Biobank data field #2734), hormone replacement therapy⁷ (#2814), hysterectomy⁵⁹ (#3591), bilateral oophorectomy⁵⁹ (#2834), body mass index⁶⁰ (#21001), diastolic and systolic

blood pressure⁶¹ (#4079 and #4080), diabetes⁶² (#2443), education⁶³ (#6138), income⁶⁴ (#738), and a composite lifestyle factor⁶⁵. The latter was expressed as a general lifestyle score that was calculated based on a number of factors (see **Supplemental Table 4**), known to increase / decrease the risk of adverse cardiovascular events. Since not all women had information on all potential confounds, we applied an imputation method using the Matlab function 'fillmissing'. That is, missing entries were replaced with the corresponding values from the nearest neighbor rows, calculated based on the pairwise Euclidean distance between rows. Imputation was applied to up to 295 women, depending on the potential confound.

Acknowledgments

EL was supported by the Swedish Collegium for Advanced Study (SCAS) and Erling-Persson Family Foundation. The data of the UK Biobank were accessed under application number #41655. The article was composed using the STROBE cohort checklist⁶⁶.

Funding

CB received funding from the South-Eastern Norway Regional Health Authority (2023037, 2022103).

Data Availability

Publicly available datasets were analyzed in this study and are available here: <https://www.ukbiobank.ac.uk>

Code Availability

The code for processing the data is available here: <https://github.com/ChristianGaser/cat12>

The code for estimating BrainAGE is available here: <https://github.com/ChristianGaser/BrainAGE>

Supplemental Material

Supplemental Table 1. Associations with BrainAGE at the initial brain scan (adjusted model*)

	R ²	Correlation (r)	Significance (p)	Slope
Reproductive Span	0.01	-0.11	<0.01	-0.11
Age at Menarche	0.02	0.14	<0.01	0.33
Age at Menopause	0.01	-0.09	<0.01	-0.09

*After removing the variance associated with the number of live births, hormone replacement therapy, hysterectomy, bilateral oophorectomy, body mass index, diastolic and systolic blood pressure, diabetes, education, income, and a composite lifestyle factor (see **Supplemental Table 4**).

Supplemental Table 2. Associations with BrainAGE over 2.35 years (adjusted model*)

	R ²	Correlation (r)	Significance (p)	Slope
Reproductive Span	0.01	-0.11	<0.01	-0.06
Age at Menarche	<0.01	0.06	0.05	0.08
Age at Menopause	0.01	-0.12	<0.01	-0.07

*After removing the variance associated with the number of live births, hormone replacement therapy, hysterectomy, bilateral oophorectomy, body mass index, diastolic and systolic blood pressure, diabetes, education, income, and a composite lifestyle factor (see **Supplemental Table 4**).

Supplemental Table 3. Ethnic background of women with longitudinal MRI data (n=1,598)

Ethnicity	Number of Women
British	1497
Any other white background	42
Irish	25
Chinese	9
Other ethnic group	5
Caribbean	5
Indian	3
Pakistani	3
African	3
Any other mixed background	3
White and Black Caribbean	2
Any other Asian background	1
White and Black African	0

Information on ethnicity was collected based on self-reports using a touchscreen questionnaire at the UK Biobank Assessment Centre.

Supplemental Table 4. A general lifestyle score was calculated based on 16 variables.

Variables	UK Biobank Data Field Number
1. Time spend watching TV	#1070
2. Sleep duration	#1160
3. Current tobacco smoking	#1239
4. Past tobacco smoking	#1249
5. Cooked vegetable intake	#1289
6. Salad / raw vegetable intake	#1299
7. Fresh fruit intake	#1309
8. Dried fruit intake	#1319
9. Oily fish intake	#1329
10. Processed meat intake	#1349
11. Beef intake	#1369
12. Lamb mutton intake	#1379
13. Pork intake	#1389
14. Alcohol intake frequency	#1558
15. Moderate activity	#884
16. Vigorous activity	#904

References

1. Thomas, M.P. & Potter, B.V. The structural biology of oestrogen metabolism. *The Journal of steroid biochemistry and molecular biology* **137**, 27-49 (2013).
2. Barth, C., Crestol, A., de Lange, A.G. & Galea, L.A.M. Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease. *Lancet Diabetes Endocrinol* **11**, 926-941 (2023).
3. Farrer, L.A., *et al.* Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* **278**, 1349-1356 (1997).
4. Brinton, R.D., Yao, J., Yin, F., Mack, W.J. & Cadenas, E. Perimenopause as a neurological transition state. *Nat Rev Endocrinol* **11**, 393-405 (2015).
5. Mosconi, L., *et al.* Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. *PLoS One* **13**, e0207885 (2018).
6. Rahman, A., *et al.* Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging study. *Neurology* **95**, e166-e178 (2020).
7. de Lange, A.G., *et al.* Women's brain aging: Effects of sex-hormone exposure, pregnancies, and genetic risk for Alzheimer's disease. *Hum Brain Mapp* **41**, 5141-5150 (2020).
8. Gong, J., Harris, K., Peters, S.A.E. & Woodward, M. Reproductive factors and the risk of incident dementia: A cohort study of UK Biobank participants. *PLoS Med* **19**, e1003955 (2022).
9. Jani, M., *et al.* Birth outcomes, puberty onset, and obesity as long-term predictors of biological aging in young adulthood. *Front Nutr* **9**, 1100237 (2022).
10. Lindseth, L.R.S., *et al.* Associations between reproductive history, hormone use, APOE epsilon4 genotype and cognition in middle- to older-aged women from the UK Biobank. *Front Aging Neurosci* **14**, 1014605 (2022).
11. Kuh, D., Cooper, R., Moore, A., Richards, M. & Hardy, R. Age at menopause and lifetime cognition: Findings from a British birth cohort study. *Neurology* **90**, e1673-e1681 (2018).
12. McLay, R.N., Maki, P.M. & Lyketsos, C.G. Nulliparity and late menopause are associated with decreased cognitive decline. *J Neuropsychiatry Clin Neurosci* **15**, 161-167 (2003).
13. Karim, R., *et al.* Effect of Reproductive History and Exogenous Hormone Use on Cognitive Function in Mid- and Late Life. *J Am Geriatr Soc* **64**, 2448-2456 (2016).
14. Ryan, J., Carriere, I., Scali, J., Ritchie, K. & Ancelin, M.L. Life-time estrogen exposure and cognitive functioning in later life. *Psychoneuroendocrinology* **34**, 287-298 (2009).
15. Branigan, G.L., Soto, M., Neumayer, L., Rodgers, K. & Brinton, R.D. Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer. *JAMA Netw Open* **3**, e201541 (2020).
16. Comasco, E., Frokjaer, V.G. & Sundstrom-Poromaa, I. Functional and molecular neuroimaging of menopause and hormone replacement therapy. *Frontiers in neuroscience* **8**, 388 (2014).
17. Nabulsi, L., *et al.* Exogenous Sex Hormone Effects on Brain Microstructure in Women: A diffusion MRI Study in the UK Biobank. *bioRxiv : the preprint server for biology*, 2020.2009.2018.304154 (2023).
18. Georgakis, M.K., *et al.* Age at menopause and duration of reproductive period in association with dementia and cognitive function: A systematic review and meta-analysis. *Psychoneuroendocrinology* **73**, 224-243 (2016).
19. Ambikairajah, A., Tabatabaei-Jafari, H., Hornberger, M. & Cherbuin, N. Age, menstruation history, and the brain. *Menopause* **28**, 167-174 (2020).
20. Gilsanz, P., *et al.* Reproductive period and risk of dementia in a diverse cohort of health care members. *Neurology* **92**, e2005-e2014 (2019).

21. Prestwood, K.M., Unson, C., Kullendorff, M. & Cushman, M. The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. *J Gerontol A Biol Sci Med Sci* **59**, 827-832 (2004).
22. Chen, S., Nilsen, J. & Brinton, R.D. Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: therapeutic implications. *Endocrinology* **147**, 5303-5313 (2006).
23. Franke, K. & Gaser, C. Ten Years of BrainAGE as a Neuroimaging Biomarker of Brain Aging: What Insights Have We Gained? *Front Neurol* **10**, 789 (2019).
24. Franke, K., Ziegler, G., Kloppel, S. & Gaser, C. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. *Neuroimage* **50**, 883-892 (2010).
25. Franke, K., Luders, E., May, A., Wilke, M. & Gaser, C. Brain maturation: Predicting individual BrainAGE in children and adolescents using structural MRI. *Neuroimage* **63**, 1305-1312 (2012).
26. Kalc, P., Dahnke, R., Hoffstaedter, F. & Gaser, C. BrainAGE: Revisited and reframed machine learning workflow. *Hum Brain Mapp* **45**, e26632 (2024).
27. Gaser, C., Franke, K., Kloppel, S., Koutsouleris, N. & Sauer, H. BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease. *PLoS One* **8**, e67346 (2013).
28. Franke, K., Ristow, M. & Gaser, C. Gender-specific impact of personal health parameters on individual brain aging in cognitively unimpaired elderly subjects. *Front Aging Neurosci* **6**, 94 (2014).
29. Luders, E., Cherbuin, N. & Gaser, C. Estimating brain age using high-resolution pattern recognition: Younger brains in long-term meditation practitioners. *NeuroImage* **134**, 508-513 (2016).
30. Franke, K., Hagemann, G., Schleussner, E. & Gaser, C. Changes of individual BrainAGE during the course of the menstrual cycle. *NeuroImage* **115**, 1-6 (2015).
31. Luders, E., *et al.* Potential Brain Age Reversal after Pregnancy: Younger Brains at 4-6Weeks Postpartum. *Neuroscience* **386**, 309-314 (2018).
32. Giannakopoulos, P., *et al.* Alzheimer resemblance atrophy index, BrainAGE, and normal pressure hydrocephalus score in the prediction of subtle cognitive decline: added value compared to existing MR imaging markers. *Eur Radiol* (2022).
33. Goto, M., *et al.* Accelerated hippocampal volume reduction in post-menopausal women: an additional study with Atlas-based method. *Radiol Phys Technol* **4**, 185-188 (2011).
34. Goto, M., *et al.* 3 Tesla MRI detects accelerated hippocampal volume reduction in postmenopausal women. *J Magn Reson Imaging* **33**, 48-53 (2011).
35. Lu, W., *et al.* Grey matter differences associated with age and sex hormone levels between premenopausal and perimenopausal women: A voxel-based morphometry study. *J Neuroendocrinol* **30**, e12655 (2018).
36. Manly, J.J., *et al.* Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. *Neurology* **54**, 833-837 (2000).
37. Boccardi, M., *et al.* Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. *Menopause* **13**, 584-591 (2006).
38. Ghidoni, R., *et al.* Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. *Maturitas* **54**, 222-228 (2006).
39. Kim, T.H., Kim, B., Kim, Y.R., Jeong, C.W. & Lee, Y.H. Gray matter differences associated with menopausal hormone therapy in menopausal women: a DARTEL-based VBM study. *Scientific reports* **13**, 1401 (2023).
40. Depypere, H., *et al.* Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease. *Alzheimers Dement* **19**, 1320-1330 (2023).

41. Xiong, J., *et al.* FSH blockade improves cognition in mice with Alzheimer's disease. *Nature* **603**, 470-476 (2022).
42. Mishra, A. & Brinton, R.D. Inflammation: Bridging Age, Menopause and APOEepsilon4 Genotype to Alzheimer's Disease. *Front Aging Neurosci* **10**, 312 (2018).
43. Scheyer, O., *et al.* Female Sex and Alzheimer's Risk: The Menopause Connection. *J Prev Alzheimers Dis* **5**, 225-230 (2018).
44. Davey, D.A. Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'? *Womens Health (Lond)* **9**, 279-290 (2013).
45. Mishra, A., *et al.* A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment. *Ageing Res Rev* **74**, 101542 (2022).
46. Middleton, L.E. & Yaffe, K. Promising strategies for the prevention of dementia. *Arch Neurol* **66**, 1210-1215 (2009).
47. Marder, K. & Sano, M. Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do? *Neurology* **54**, 2035-2037 (2000).
48. Resnick, S.M. & Henderson, V.W. Hormone therapy and risk of Alzheimer disease: a critical time. *JAMA* **288**, 2170-2172 (2002).
49. Yaffe, K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? *Ann N Y Acad Sci* **949**, 215-222 (2001).
50. Yaffe, K., Haan, M., Byers, A., Tangen, C. & Kuller, L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. *Neurology* **54**, 1949-1954 (2000).
51. Nerattini, M., *et al.* Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia. *Front Aging Neurosci* **15**, 1260427 (2023).
52. Barth, C. & de Lange, A.G. Towards an understanding of women's brain aging: the immunology of pregnancy and menopause. *Front Neuroendocrinol* **58**, 100850 (2020).
53. Barth, C., Villringer, A. & Sacher, J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Frontiers in neuroscience* **9**(2015).
54. Fry, A., *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026-1034 (2017).
55. Alfaro-Almagro, F., *et al.* Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. *NeuroImage* **166**, 400-424 (2018).
56. Gaser, C., Dahnke, R., Thompson, P.M., Kurth, F. & Luders, E. CAT – A Computational Anatomy Toolbox for the Analysis of Structural MRI Data. *bioRxiv* **2022.06.11.495736**(2022).
57. Rasmussen, C.E.W., C. K. I. Gaussian Processes for Machine Learning. *MIT Press* (2006).
58. de Lange, A.G., *et al.* Population-based neuroimaging reveals traces of childbirth in the maternal brain. *Proc Natl Acad Sci U S A* **116**, 22341-22346 (2019).
59. Rocca, W.A., Grossardt, B.R., Shuster, L.T. & Stewart, E.A. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. *Neurodegener Dis* **10**, 175-178 (2012).
60. Tungler, A., *et al.* Body mass index but not genetic risk is longitudinally associated with altered structural brain parameters. *Scientific reports* **11**, 24246 (2021).
61. Cherbuin, N., *et al.* Optimal Blood Pressure Keeps Our Brains Younger. *Front Aging Neurosci* **13**, 694982 (2021).
62. Antal, B., *et al.* Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses. *Elife* **11**(2022).
63. Chan, M.Y., *et al.* Long-term prognosis and educational determinants of brain network decline in older adult individuals. *Nat Aging* **1**, 1053-1067 (2021).
64. Busby, N., *et al.* Lower socioeconomic status is associated with premature brain aging. *Neurobiology of aging* **130**, 135-140 (2023).

65. Foster, H.M.E., *et al.* The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort. *Lancet Public Health* **3**, e576-e585 (2018).
66. von Elm, E., *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* **61**, 344-349 (2008).